Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- Registration Number
- NCT06251180
- Lead Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Brief Summary
This is an open-label, multicentre Phase Ib study to evaluate the safety and preliminary efficacy of new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib in combination to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) in adult patients with newly diagnosed, previously untreated B-cell Non-Hodgkin Lymphoma \[Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL) or Mantle Cell Lymphoma (MCL)\].
- Detailed Description
OUTLINE:
Dose escalation portion(Part A): In the dose escalation portion of the study, the escalating doses of Rocbrutinib combined with R-CHOP may be explored, using the 3+3 principle for dose determination. If dose escalation is acceptable, and subsequently will determine the recommended Phase 2 dose.
Dose expansion portion(Part B): This will be conducted as a multicenter, open-label study, including three cohorts(Cohort 1: non-GCB DLBCL; Cohort 2: MZL; Cohort 3: MCL). Eligible subjects will receive Rocbrutinib combined with R-CHOP for 6 cycles, then Rocbrutinib plus Rituximab for 2 cycles, and followed by Rocbrutinib maintenance for 2 years.
After completion of study treatment, patients are followed up every 12 weeks for 1 year, then every 24 weeks for 4 year.
PRIMARY OBJECTIVES:
I. To evaluate the safety of Rocbrutinib in combination to R-CHOP in B-cell Non-Hodgkin Lymphoma, including the maximum tolerated dose (MTD), dose limiting toxicities(DLT), adverse events (AEs), clinically significant laboratory abnormalities.
2. To determine the recommended dose. 3. To determine the pharmacokinetic characteristics of Rocbrutinib in combination to R-CHOP.
SECONDARY OBJECTIVES:
I. To determine the overall response rate, the complete response rate, duration of remission, survival outcomes (progression free survival, event free survival, overall survival) in DLBCL/ Non-germinal Center(non-GCB) DLBCL.
2. To determine the overall response rate, the complete response rate, duration of remission, survival outcomes (progression free survival, event free survival, overall survival) in MZL.
3. To determine the overall response rate, the complete response rate, duration of remission, survival outcomes (progression free survival, event free survival, overall survival) in MCL.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 112
- Participants was histopathologically diagnosed with any of the following diseases: DLBCL, MZL or MCL (if enrolled in the dose expansion phase, histological confirmation of non-GCB subtype), and have not previously received anti-tumor systemic therapy or local radiation therapy for the above diseases.
- Participants must have at least one measurable lesion.
- ECOG physical status score 0-2.
- Life expectancy ≥6 months.
- International Prognostic Index (IPI) score ≥ 2 (only participants with DLBCL in dose expansion portion).
- Adequate coagulation, liver, kidney, and hematopoietic functions：PT and APTT <1.5x ULN; serum bilirubin <1.5x ULN except in participants with Gilbert's syndrome who must have a serum bilirubin of <3x ULN, AST and ALT ≤ 3x ULN or < 5x ULN if hepatic involvement are present; serum creatinine (Scr) ≤1.5 x ULN, or calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula.; ANC≥1500/mm3, hemoglobin≥8.0 g/dL, and platelets >100,000/mm3 unless deemed related to lymphoma involvement in the bone marrow and felt potentially reversible by the treating physician.
- Women of childbearing potential must have a negative serum or urine (beta-human chorionic gonadotropin [beta-hCG]) at screening.
- Women of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective contraceptive measures of during and after the study (90 days after the last dose of ROCBRUTINIB and 12 months after the last dose of Rituximab). Men must agree to not donate sperm during and for up to 90 days after he last dose of ROCBRUTINIB.
- Participants voluntarily enrolled and signed the informed consent form, and followed the trial treatment and visits.
- Participants are allergic to Rocbrutinib or any of its excipients; Participants who are assessed by the investigator as being unable to tolerate the R-CHOP regimen.
- Participants with known central nervous system involvement with lymphoma. or diagnosis of primary central nervous system lymphoma (PCNSL) or primary mediastinal large B-cell lymphoma (PMBL).
- Participants with DLBCL had a history of indolent lymphoma such as FL or CLL (Richter's transformation), or was histopathologically comfirmed with FL (regardless of grade) coexistentially.
- Prior treatment with solid organ transplantation or hematopoietic stem cell transplantation(HSCT) ; expected HSCT during the study.
- Major surgery within 4 weeks of study entry or expected major surgery during the study.
- Prior another non-antitumor or medical instruments clinical trials within 4 weeks.
- Known bleeding diseases (such as von Willebrand's disease or hemophilia A, hemophilia B, etc.), or have bleeding tendency.
- Prior treatment with warfarin or equivalent vitamin K antagonists within 14 days; requires anticoagulation with warfarin or equivalent vitamin K antagonists.
- Prior treatment with strong/moderate CYP3A4 inhibitors within 5 days or prior foods with inhibitory effects on CYP3A4 within 3 days at screening; requires chronic treatment with moderate/strong CYP3A inhibitors or inducers, or OATP1B1/OATP1B3 sensitive substrates during the study.
- Participants with other malignancies other than the target indications of this study within the past three years.
- Prior treatment with the cumulative dose of doxorubicin ≥150 mg/m2 (or other anthracyclines at doses converted based on cumulative cardiac toxicity)
- Any serious medical condition including but not limited to uncontrolled hypertension, uncontrolled congestive heart failure or ≥Class 2 cardiac disease as defined by the New York Heart Association Functional Classification or LVEF less than 40%, uncontrolled or symptomatic arrhythmias with corrected QT interval (QTc) > 480 msec, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, COPD, renal failure, severe hepatic disease, uncontrolled active infection, active hemorrhage.
- Known HIV infection, or syphilis infection, or hepatitis B DNA or hepatitis C RNA positive.
- Known diseases that affect drug swallowing or absorption.
- Unfit to participate in this study in the investigator's opinion.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Dose Escalation Rocbrutinib Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP Dose Expansion [MCL] Rituximab Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MCL] Vincristin Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Escalation Rituximab Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP Dose Expansion [non-GCB DLBCL] Rituximab Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [non-GCB DLBCL] Cyclophosphamide Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [non-GCB DLBCL] Prednisone Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MZL] Vincristin Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MZL] Prednisone Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [non-GCB DLBCL] Rocbrutinib Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MZL] Rocbrutinib Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MCL] Rocbrutinib Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Escalation Cyclophosphamide Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP Dose Escalation Vincristin Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP Dose Escalation doxorubicin Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP Dose Escalation Prednisone Patients with DLBCL or MCL or MZL receive Rocbrutinib（at escalating dose）+R-CHOP Dose Expansion [non-GCB DLBCL] Vincristin Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [non-GCB DLBCL] doxorubicin Patients with non-GCB DLBCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MCL] doxorubicin Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MCL] Cyclophosphamide Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MCL] Prednisone Patients with MCL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MZL] Cyclophosphamide Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MZL] doxorubicin Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP Dose Expansion [MZL] Rituximab Patients with MZL receive Rocbrutinib（at recommended dose )+R-CHOP
- Primary Outcome Measures
Name Time Method Recommended Dose Up to 1.5 years Recommended Dose will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase.
MTD Up to 21 days after the initial dose Standard phase I 3+3 design.
Incidence of AEs From first dose of study drug to 28 days after the last dose of study drugs Type, frequency and severity of AEs, relationship of AEs to study treatment Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Type, frequency and severity of AEs, relationship of AEs to study treatment Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0
Cmax of Rocbrutinib Up to 24 hours post dose Maximum plasma concentration (Cmax) of Rocbrutinib.
Incidence of clinically significant laboratory abnormalities From first dose of study drug to 28 days after last dose of study drug Clinically significant abnormalities in hematology, chemistry, coagulation and urinalysis.
Tmax of Rocbrutinib Up to 24 hours post dose Time to maximum plasma concentration (Tmax) of Rocbrutinib.
T1/2 of Rocbrutinib Up to 24 hours post dose The terminal elimination half-life (t1/2).
AUC0-t of Rocbrutinib Up to 24 hours post dose Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration of Rocbrutinib.
CL/F of Rocbrutinib Up to 24 hours post dose Apparent clearance (CL/F) of Rocbrutinib.
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) Evey 2 cycles for 8 cycles, and followed every 3cyles for 24 months Assessment using the Lugano Response Criteria for Malignant Lymphoma.
Duration of Response(DOR) Measured from the date of the first remission to the date of earliest disease progression or death, and assessed up to 5 years. DOR is defined as the number of days from the date of the first remission to the date of earliest disease progression or death.
Complete remission (CR) Evey 2 cycles for 8 cycles, and followed every 3cyles for 24 months Assessment using the Lugano Response Criteria for Malignant Lymphoma.
Progression-Free Survival(PFS) Measured from the date of first dose of study drug to the date of earliest disease progression or death or last visit, and assessed up to 5 years. PFS is defined as the number of days from the date of the first dose of study drug to the date of earliest disease progression or death.
Event-free Survival (EFS) Measured from the date of first dose to the date of earliest evidence of disease progression, initiation of new non-protocol-specified antitumor therapy without documented progression, death, and for up to 5 years after the last subject is enrolled. EFS is defined as the number of days from the date of first dose to the date of earliest evidence of disease progression/relapse, or initiation of new non-protocol-specified antitumor therapy without documented progression, or death.
Overall survival (OS) Measured from the date of date of first dose to the date of death or last visit, and for up to 5 years after the last subject is enrolled. OS is defined as the number of days from the date of first dose to the date of death.
Trial Locations
- Locations (1)
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China